137 related articles for article (PubMed ID: 38407902)
21. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.
Zhang XS; Zhou HC; Wei P; Chen L; Ma WH; Ding L; Liang SC; Chen BD
World J Gastrointest Oncol; 2023 Dec; 15(12):2138-2149. PubMed ID: 38173440
[TBL] [Abstract][Full Text] [Related]
22. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Physicochemical Characterization, In Vitro Membrane Permeation, and In Vitro Human Skin Cell Culture of a Novel TOPK Inhibitor, HI-TOPK-032.
Eedara BB; Manivannan B; Alabsi W; Sun B; Curiel-Lewandrowski C; Zhang T; Bode AM; Mansour HM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958502
[TBL] [Abstract][Full Text] [Related]
24. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
25. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma.
Zhai Y; He K; Huang L; Shang X; Wang G; Yuan G; Han ZG
Liver Int; 2022 Nov; 42(11):2524-2537. PubMed ID: 36002393
[TBL] [Abstract][Full Text] [Related]
26. TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1.
Li J; Sun H; Fu M; Zheng Z; Xu C; Yang K; Liu Y; Xuan Z; Bai Y; Zheng J; Zhao Y; Shi Z; Shao C
iScience; 2023 Jul; 26(7):107185. PubMed ID: 37404377
[TBL] [Abstract][Full Text] [Related]
27. Non-viral
Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells.
Qin A; Qin Y; Lee J; Musket A; Ying M; Krenciute G; Marincola FM; Yao ZQ; Musich PR; Xie Q
J Transl Med; 2023 Oct; 21(1):682. PubMed ID: 37779207
[TBL] [Abstract][Full Text] [Related]
29. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
30. Eomesodermin(lo) CTLA4(hi) Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates.
Ezzelarab MB; Lu L; Guo H; Zahorchak AF; Shufesky WF; Cooper DK; Morelli AE; Thomson AW
Transplantation; 2016 Jan; 100(1):91-102. PubMed ID: 26680373
[TBL] [Abstract][Full Text] [Related]
31. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
32. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
33. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
34. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β.
Alabanza LM; Xiong Y; Vu B; Webster B; Wu D; Hu P; Zhu Z; Dropulic B; Dash P; Schneider D
Front Immunol; 2022; 13():832645. PubMed ID: 35222421
[TBL] [Abstract][Full Text] [Related]
35. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
36. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.
Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
Elife; 2023 Feb; 12():. PubMed ID: 36779699
[TBL] [Abstract][Full Text] [Related]
38. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
39. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
[TBL] [Abstract][Full Text] [Related]
40. A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma.
Konduri V; Joseph SK; Byrd TT; Nawas Z; Vazquez-Perez J; Hofferek CJ; Halpert MM; Liu D; Liang Z; Baig Y; Salsman VS; Oyewole-Said D; Tsimelzon A; Burns BA; Chen C; Levitt JM; Yao Q; Ahmed NM; Hegde M; Decker WK
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]